1 188

Cited 1162 times in

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

Authors
 Robert Pirker  ;  Jose R Pereira  ;  Aleksandra Szczesna  ;  Joachim von Pawel  ;  Maciej Krzakowski  ;  Rodryg Ramlau  ;  Ihor Vynnychenko  ;  Keunchil Park  ;  Chih-Teng Yu  ;  Valentyn Ganul  ;  Jae-Kyung Roh  ;  Emilio Bajetta  ;  Kenneth O'Byrne  ;  Filippo de Marinis  ;  Wilfried Eberhardt  ;  Thomas Goddemeier  ;  Michael Emig  ;  Ulrich Gatzemeier 
Citation
 Lancet, Vol.373(9674) : 1525-1531, 2009 
Journal Title
 Lancet 
ISSN
 0140-6736 
Issue Date
2009
MeSH
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal/therapeutic use* ; Antibodies, Monoclonal, Humanized ; Antineoplastic Agents/therapeutic use* ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use* ; Carcinoma, Non-Small-Cell Lung/drug therapy* ; Carcinoma, Non-Small-Cell Lung/mortality ; Carcinoma, Non-Small-Cell Lung/pathology ; Cetuximab ; Cisplatin/administration & dosage ; Female ; Humans ; Lung Neoplasms/drug therapy* ; Lung Neoplasms/mortality ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Neoplasm Staging ; Proportional Hazards Models ; Receptor, Epidermal Growth Factor/analysis ; Receptor, Epidermal Growth Factor/antagonists & inhibitors ; Receptor, Epidermal Growth Factor/drug effects ; Survival Analysis ; Survival Rate ; Treatment Outcome ; Vinblastine/administration & dosage ; Vinblastine/analogs & derivatives ; Young Adult
Abstract
BACKGROUND: Use of cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), has the potential to increase survival in patients with advanced non-small-cell lung cancer. We therefore compared chemotherapy plus cetuximab with chemotherapy alone in patients with advanced EGFR-positive non-small-cell lung cancer. METHODS: In a multinational, multicentre, open-label, phase III trial, chemotherapy-naive patients (>or=18 years) with advanced EGFR-expressing histologically or cytologically proven stage wet IIIB or stage IV non-small-cell lung cancer were randomly assigned in a 1:1 ratio to chemotherapy plus cetuximab or just chemotherapy. Chemotherapy was cisplatin 80 mg/m(2) intravenous infusion on day 1, and vinorelbine 25 mg/m(2) intravenous infusion on days 1 and 8 of every 3-week cycle) for up to six cycles. Cetuximab-at a starting dose of 400 mg/m(2) intravenous infusion over 2 h on day 1, and from day 8 onwards at 250 mg/m(2) over 1 h per week-was continued after the end of chemotherapy until disease progression or unacceptable toxicity had occurred. The primary endpoint was overall survival. Analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00148798. FINDINGS: Between October, 2004, and January, 2006, 1125 patients were randomly assigned to chemotherapy plus cetuximab (n=557) or chemotherapy alone (n=568). Patients given chemotherapy plus cetuximab survived longer than those in the chemotherapy-alone group (median 11.3 months vs 10.1 months; hazard ratio for death 0.871 [95% CI 0.762-0.996]; p=0.044). The main cetuximab-related adverse event was acne-like rash (57 [10%] of 548, grade 3). INTERPRETATION: Addition of cetuximab to platinum-based chemotherapy represents a new treatment option for patients with advanced non-small-cell lung cancer. FUNDING: Merck KGaA.
Full Text
http://www.sciencedirect.com/science/article/pii/S0140673609605699
DOI
10.1016/S0140-6736(09)60569-9
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Roh, Jae Kyung(노재경)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/104868
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse